Evexia AGM Resolutions Pass With Majority

Evexia Lifecare Limited has disclosed the voting results of its 34th Annual General Meeting (AGM), which was held on May 15, 2026, via video conferencing. The meeting transacted 11 business items, and the company has now announced the outcomes following the conclusion of remote e-voting and voting during the AGM.

Voting Summary

The remote e-voting facility was provided by National Securities Depository Limited (NSDL) to members holding shares as on the cut-off date of May 8, 2026. The remote e-voting period commenced on May 12, 2026, and concluded on May 14, 2026. The Scrutinizer, M/s Brajesh Gupta & Co., verified the votes cast through remote e-voting and during the meeting. The consolidated results indicate that all resolutions were passed with the requisite majority.

Resolution Outcomes

The voting results for the key resolutions are detailed below:

Resolution Description	Votes For	Votes Against	% For
Adoption of Financial Statements (2024-25)	166,618	35,619	82.39%
Re-appointment of Director (Rotation)	164,018	38,219	81.10%
Appointment of Statutory Auditors	167,477	34,760	82.81%
Re-appointment of Managing Director	160,813	41,424	79.52%
Appointment of Secretarial Auditors	162,813	39,424	80.51%

Special Business Results

Special resolutions regarding authorizations for loans, investments, and the alteration of the Memorandum of Association were also approved. For instance, the resolution to authorize the Board to grant loans under Section 185 of the Companies Act, 2013, received 160,819 votes in favor (79.52%) and 41,418 votes against (20.48%). The resolution to alter the Object Clause of the Memorandum of Association passed with 164,278 votes in favor (81.23%) and 37,959 votes against (18.77%).

The Scrutinizer's report, dated May 18, 2026, confirmed that the proceedings were conducted in compliance with the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results have been submitted to BSE Limited.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+4.38%	+30.00%	+104.29%	-14.88%	-47.23%	-88.85%

Evexia Lifecare Limited held its Board of Directors meeting on May 09, 2026, and approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The company disclosed that advertisements for these results were published in the Financial Express (English and Gujarati) on May 14, 2026, with a corrigendum published on May 15, 2026. The results were audited by Tejas K. Soni and Company, Chartered Accountants, who issued a qualified audit report on both standalone and consolidated financial statements.

Standalone Financial Performance

On a standalone basis, the company reported revenue from operations of ₹10,546.47 Lakhs for the full year, compared to ₹8,388.68 Lakhs in the previous year. Total revenue, including other income, stood at ₹10,635.03 Lakhs against ₹8,402.33 Lakhs. Net profit for the year rose to ₹152.10 Lakhs from ₹72.79 Lakhs. The following table presents the key standalone financial metrics:

Metric:	Q4 FY26 (Audited)	Q3 FY26 (Unaudited)	Q4 FY25 (Audited)	FY26 (Audited)	FY25 (Audited)
Revenue from Operations (₹ Lakhs):	3,517.94	2,455.92	1,517.93	10,546.47	8,388.68
Other Income (₹ Lakhs):	54.63	25.96	3.41	88.56	13.65
Total Revenue (₹ Lakhs):	3,572.57	2,481.88	1,521.34	10,635.03	8,402.33
Total Expenses (₹ Lakhs):	3,518.03	2,430.84	1,469.26	10,429.48	8,281.95
Profit Before Tax (₹ Lakhs):	56.54	55.04	32.08	205.55	120.38
Net Profit (₹ Lakhs):	46.96	40.73	18.16	152.10	72.79
Basic EPS (₹):	0.003	0.002	0.001	0.008	0.004
Diluted EPS (₹):	0.003	0.002	0.001	0.008	0.004

Consolidated Financial Performance

On a consolidated basis, the company reported revenue from operations of ₹11,027.50 Lakhs for the full year against ₹8,659.04 Lakhs in the prior year. Total consolidated revenue stood at ₹11,027.53 Lakhs. Consolidated net profit for the year was ₹162.13 Lakhs compared to ₹41.25 Lakhs in the previous year. Profit attributable to owners of the parent stood at ₹158.88 Lakhs for the year. The key consolidated financial metrics are summarised below:

Metric:	Q4 FY26 (Audited)	Q3 FY26 (Unaudited)	Q4 FY25 (Audited)	FY26 (Audited)	FY25 (Audited)
Revenue from Operations (₹ Lakhs):	3,678.84	2,524.38	2,361.19	11,027.50	8,659.04
Total Revenue (₹ Lakhs):	3,688.51	2,550.34	2,361.19	11,027.53	8,673.11
Total Expenses (₹ Lakhs):	3,598.73	2,510.89	2,316.88	10,607.70	8,881.26
Profit Before Tax (₹ Lakhs):	89.79	39.45	44.31	219.85	91.86
Net Profit (₹ Lakhs):	77.85	29.19	30.89	162.13	41.25
Profit Attributable to Owners (₹ Lakhs):	74.60	29.19	30.89	158.88	41.25
Basic EPS (₹):	0.004	0.002	0.003	0.008	0.002
Diluted EPS (₹):	0.004	0.002	0.002	0.008	0.002

Audit Qualifications and Key Concerns

The statutory auditor issued a qualified opinion on both standalone and consolidated financial results. Key qualifications include: loan receivables of ₹735.13 Lakhs with significant credit risk for which no expected credit loss assessment has been made; trade receivables of ₹2,943.89 Lakhs similarly lacking an expected credit loss assessment; investments in unquoted equity shares of ₹87.39 Lakhs for which fair valuation cannot be determined; and exposure of ₹127.70 Lakhs in subsidiary Kavit Edible Oil Limited, which has suspended manufacturing operations since March 2019 and carries a negative net worth, raising going concern doubts. The auditors also noted material misstatements, non-compliance with financial reporting frameworks, and inability to verify significant transactions due to lack of audit evidence. The management's impact assessment for all qualifications was stated as not ascertainable, and the qualifications are repetitive in nature.

FCCB Extension and Other Notes

During the year, the company entered into an arrangement with Foreign Currency Convertible Bond (FCCB) holders to extend the conversion/redemption period from March 2, 2026 to February 3, 2028, subject to applicable regulatory requirements. The management has evaluated the accounting impact of this extension and believes it does not have any material adverse impact on the financial statements.